Cepheid said this week that it has launched Xpert HPV, a one-hour molecular test for cervical cancer-related human papillomaviruses, in Europe after receiving CE IVD marking.

The assay, which runs on the company's GeneXpert system, closely follows the launch of the company's combined Xpert assay for chlamydia and gonorrhea, and should enable Cepheid to further compete in the women's health market with established players such as Roche, Hologic, Qiagen, and Abbott.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.